WallStreetZenWallStreetZen

NASDAQ: DYN
Dyne Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for DYN

Based on 8 analysts offering 12 month price targets for Dyne Therapeutics Inc.
Min Forecast
$29.00+13.06%
Avg Forecast
$39.63+54.48%
Max Forecast
$56.00+118.32%

Should I buy or sell DYN stock?

Based on 8 analysts offering ratings for Dyne Therapeutics Inc.
Strong Buy
Strong Buy
6 analysts 75%
Buy
2 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DYN stock forecasts and price targets.

DYN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-06
lockedlocked$00.00+00.00%2024-05-06
lockedlocked$00.00+00.00%2024-05-03
lockedlocked$00.00+00.00%2024-04-30
lockedlocked$00.00+00.00%2024-03-07Find Out Why
Stifel Nicolaus
Bottom 10%
10
Strong BuyMaintains$41.00+59.84%2024-03-06
Piper Sandler
Bottom 3%
3
Strong BuyMaintains$29.00+13.06%2024-03-06
Raymond James
Top 10%
91
Strong BuyMaintains$56.00+118.32%2024-01-04Find out why

1 of 1

Forecast return on equity

Is DYN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.94%

Forecast return on assets

Is DYN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

DYN revenue forecast

What is DYN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$105.1M
Avg 2 year Forecast
$120.7M
Avg 3 year Forecast
$259.2M

DYN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DYN$25.65$39.63+54.48%Strong Buy
MRVI$8.96$10.83+20.90%Strong Buy
CGON$33.95$61.75+81.89%Strong Buy
SANA$10.04$13.50+34.46%Buy
NTLA$23.88$59.75+150.21%Buy
View Top Biotech Stocks

Dyne Therapeutics Stock Forecast FAQ

Is Dyne Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: DYN) stock is to Strong Buy DYN stock.

Out of 8 analysts, 6 (75%) are recommending DYN as a Strong Buy, 2 (25%) are recommending DYN as a Buy, 0 (0%) are recommending DYN as a Hold, 0 (0%) are recommending DYN as a Sell, and 0 (0%) are recommending DYN as a Strong Sell.

If you're new to stock investing, here's how to buy Dyne Therapeutics stock.

What is DYN's revenue growth forecast for 2025-2027?

(NASDAQ: DYN) Dyne Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.75%.

Dyne Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast DYN's revenue for 2025 to be $9,181,293,775, with the lowest DYN revenue forecast at $9,181,293,775, and the highest DYN revenue forecast at $9,181,293,775. On average, 2 Wall Street analysts forecast DYN's revenue for 2026 to be $10,550,055,416, with the lowest DYN revenue forecast at $2,438,674,661, and the highest DYN revenue forecast at $18,661,436,171.

In 2027, DYN is forecast to generate $22,652,201,249 in revenue, with the lowest revenue forecast at $16,744,261,094 and the highest revenue forecast at $28,560,141,404.

What is DYN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: DYN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is DYN's Price Target?

According to 8 Wall Street analysts that have issued a 1 year DYN price target, the average DYN price target is $39.63, with the highest DYN stock price forecast at $56.00 and the lowest DYN stock price forecast at $29.00.

On average, Wall Street analysts predict that Dyne Therapeutics's share price could reach $39.63 by May 6, 2025. The average Dyne Therapeutics stock price prediction forecasts a potential upside of 54.48% from the current DYN share price of $25.65.

What is DYN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: DYN) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.